GH Secretagogues Billing & Prior-Auth Playbook

What Is the GH Secretagogues Drug Class?

Growth hormone secretagogues are a pharmacologically heterogeneous group of agents that increase GH secretion by acting on one or both of two upstream receptors: the growth hormone-releasing hormone receptor (GHRH-R) and the ghrelin receptor (also called the GH secretagogue receptor, GHSR-1a). Unlike recombinant human GH (rhGH, somatropin), these molecules preserve the pulsatile architecture of GH release and keep IGF-1 elevations within a more physiologic range, which may reduce the side-effect burden seen with exogenous GH.

Tesamorelin's phase 3 program (N=816 in two randomized trials) demonstrated a mean trunk fat reduction of 15.2% versus 1.2% placebo at 26 weeks (P<0.001), establishing the clinical proof-of-concept for this class in adults [1].

GHRH Analogs

Sermorelin (GHRH 1-29 NH2) and tesamorelin (a stabilized GHRH analog with a trans-3-hexenoic acid modification) both bind the GHRH-R on pituitary somatotrophs. Sermorelin was FDA-approved for pediatric GH deficiency until 2008, when Serono withdrew it for commercial rather than safety reasons [2]. Tesamorelin received FDA approval in 2010 for HIV-associated lipodystrophy and remains the only GHS with an active NDA.

Ghrelin Mimetics (GHRPs)

GHRP-2, GHRP-6, hexarelin, and ipamorelin bind GHSR-1a. Ipamorelin is the preferred clinical agent because it produces selective GH release without the cortisol, prolactin, or ACTH co-secretion seen with older GHRPs [3]. A 2001 study in healthy adults confirmed ipamorelin's selectivity profile at doses from 1 to 30 mcg/kg IV, with no statistically significant cortisol or prolactin elevation at any dose tested [3].

Orally Active Small Molecules

MK-677 (ibutamoren) is a non-peptide GHSR-1a agonist that survives first-pass metabolism and can be dosed orally at 10-25 mg/day. The 12-month MECA trial (N=65 elderly adults) showed that 25 mg/day increased IGF-1 by approximately 40% and improved lean body mass by 1.1 kg versus placebo [4]. MK-677 is not FDA-approved and is not schedulable as a controlled substance, creating a regulatory gray zone for prescribers.

FDA Approval Status and Legal Prescribing Framework

Understanding which agents are approved, which are permissibly compounded, and which fall outside both categories is the first step before any billing encounter.

Tesamorelin: The Only Reimbursable Anchor

Tesamorelin (Egrifta SV, Theratechnologies) holds FDA approval under NDA 022505 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy [5]. The labeled dose is 2 mg subcutaneous daily. Because it carries a commercial NDC, it can be submitted to pharmacy benefit managers and, in some state Medicaid programs, to medical benefit under HCPCS code J3590 (unclassified biologic) pending a specific J-code assignment.

Sermorelin and Ipamorelin: 503A Compounding

Sermorelin and ipamorelin are available only through FDA-registered 503A or 503B compounding pharmacies. The FDA's 2023 memorandum on bulk drug substances clarified that both sermorelin and ipamorelin remained on the 503A bulk-list as of publication, allowing patient-specific compounding [6]. Prescribers must write a patient-specific prescription; no commercially manufactured product exists. This compounding status means no NDC, no commercial formulary, and essentially no traditional insurance reimbursement pathway.

MK-677 and Regulatory Risk

MK-677 is not on any FDA bulk-substance list and is not approved as a drug. The FDA has issued warning letters to firms marketing it as a research chemical or supplement. Prescribing MK-677 for human use in a clinical context carries regulatory exposure and is outside the scope of telehealth billing discussions here.

Diagnosis Coding Strategy for GHS Prescribing

Coding accuracy is the single largest determinant of prior-auth success and audit defense. Vague codes like Z00.00 (routine adult health exam) will not support medical necessity for any GHS.

ICD-10 Codes That Build Medical Necessity

The following codes are defensible for GHS prescribing when supported by objective labs and clinical documentation:

• E23.0 (Hypopituitarism): Use when a formal stimulation test (glucagon stimulation or insulin tolerance test) confirms GH deficiency. Adult GH deficiency criteria require a GH peak <3 ng/mL on stimulation testing per Endocrine Society guidelines [7].
• E34.8 (Other specified endocrine disorders): Used when IGF-1 is low-normal or below age-adjusted reference range but full pituitary workup has not been performed. Pair with symptom codes.
• R53.83 (Other fatigue): Symptom-level code; never stand alone.
• M62.50 (Muscle wasting and atrophy, unspecified): Supports body-composition indications when DXA documents lean mass deficit.
• B20 (HIV disease): Required for tesamorelin; pair with E65 (obesity) or specific lipodystrophy codes.
• Z79.899 (Long-term use of other medication): Add as a secondary code once the agent is established to document ongoing use.

Documentation Anchors Payers Expect

Payers conducting retrospective audits look for four specific elements in the chart note: (1) an IGF-1 result with the lab reference range printed, (2) a symptom severity assessment (a validated tool like the Quality of Life-AGHDA questionnaire or a structured narrative), (3) evidence that lifestyle intervention was attempted for at least 90 days, and (4) the prescriber's clinical reasoning connecting the diagnosis to the chosen agent. Missing any one of these four elements is the leading cause of prior-auth denial in GHS cases reviewed by the HealthRX medical team.

Prior Authorization: Payer-by-Payer Approach

Prior auth for GHS agents is genuinely difficult when the product is compounded because payers do not have a formulary entry to approve against. The strategy therefore shifts from "get the drug approved" to "get the visit and lab monitoring approved while the patient pays cash for the compound."

Commercial Insurance: What to Request

For patients with commercial insurance seeking tesamorelin, submit a PA through the pharmacy benefit using the commercial NDC (71770-0101-30 for Egrifta SV 2 mg). The PA form will ask for:

• HIV diagnosis confirmation (B20)
• Baseline abdominal CT or DEXA documenting visceral fat
• Prescriber attestation that the patient is on stable antiretroviral therapy
• Absence of active malignancy

Approval rates for on-label tesamorelin are roughly 70-80% on first submission when documentation is complete, based on published Theratechnologies outcomes data [8].

For off-label GHS (sermorelin, ipamorelin), commercial PA for the drug itself is not a realistic goal. Instead, submit PA for the diagnostic workup (stimulation testing, IGF-1 panel, DXA) using CPT 80430 (ACTH stimulation panel), 84305 (IGF-1), and 77080 (DXA axial). Getting monitoring labs covered reduces the total cash burden on patients who are self-paying for the compound.

Medicare and Medicaid

Medicare Part B does not cover compounded drugs prepared from bulk substances under 503A for outpatient use. Part D formularies will not carry a compounded preparation with no NDC. Tesamorelin may be coverable under Part B as an injectable administered in the office setting, billed under J3590, but this pathway requires the drug to be purchased by the practice and administered on-site, which is logistically impractical for a daily subcutaneous injection.

Medicaid coverage varies by state. As of 2024, fewer than 8 states have a specific PA pathway for tesamorelin in HIV lipodystrophy within their Medicaid formularies, based on review of publicly available state PDL documents.

Appeals: The Three-Document Rule

When a PA denial arrives, the appeal should attach exactly three documents: (1) a signed letter of medical necessity from the prescriber citing the Endocrine Society's 2011 GH deficiency guideline [7] and the relevant IGF-1 result, (2) the peer-reviewed publication most directly supporting the use (for tesamorelin, the Falutz et al. NEJM 2007 trial [1]; for sermorelin, the Walker et al. 1990 NEJM pediatric data [2]), and (3) a cost-effectiveness statement noting that compounded GHS costs roughly $200-$350/month versus $4,000-$6,000/month for rhGH, reducing payer liability if the indication is accepted.

Compounding Pharmacy Compliance for Prescribers

Prescribers bear legal exposure when they write for compounded GHS if the pharmacy is not properly registered or the prescription lacks required elements.

Verifying 503A vs. 503B Status

A 503A pharmacy compounds for individual patients on a prescription-by-prescription basis. A 503B outsourcing facility can produce larger batches without a patient-specific Rx, but the product must still be dispensed to a licensed prescriber or healthcare entity, not directly to patients. For telehealth GHS prescribing, 503A is the standard pathway. Verify any pharmacy's registration at the FDA's database of registered outsourcing facilities or through your state board of pharmacy before routing prescriptions [6].

Required Prescription Elements

A valid 503A GHS prescription must include: patient name and date of birth, the specific active pharmaceutical ingredient and its strength (e.g., ipamorelin 200 mcg/mL), the route and dosing instructions (e.g., 0.3 mL subcutaneous injection at bedtime), quantity dispensed, prescriber DEA number if applicable, and a note indicating "for individual patient use" to confirm the 503A pathway. Ipamorelin is not a controlled substance, so DEA number is technically optional but many pharmacies request it for verification.

Concentration and Stability Considerations

Compounded ipamorelin is typically prepared at 2 mg/mL in bacteriostatic water with a 30-day beyond-use date (BUD) when refrigerated, per USP 797 standards. Some 503A pharmacies extend BUD to 90 days when lyophilized (powder) preparations are dispensed with separate diluent. Prescribers should specify the preparation form preferred to avoid inadvertent dispensing of an incompatible formulation. Tesamorelin from Theratechnologies is supplied as a lyophilized powder reconstituted with provided sterile water, stable for 24 hours post-reconstitution at room temperature [5].

Dosing Reference for Common GHS Agents

Precision dosing is a billing and compliance asset: dose-specific documentation supports medical necessity and differentiates a therapeutic prescription from wellness supplementation.

Ipamorelin

The most studied subcutaneous dose range is 100-300 mcg per injection, typically dosed once daily at bedtime to align with the nocturnal GH pulse. Some protocols use twice-daily dosing (morning and bedtime) at 100 mcg per injection to maintain more consistent IGF-1 elevation. No randomized controlled trial in adults has compared once-daily versus twice-daily ipamorelin dosing directly, though the selectivity data from Raun et al. [3] used single-dose IV protocols.

Combination with a GHRH analog (most commonly CJC-1295 with DAC, or modified GRF 1-29) is common in clinical practice because the two receptor pathways have additive effects on GH pulse amplitude. A combination preparation at ipamorelin 150 mcg / CJC-1295 100 mcg per injection is a standard 503A formulation.

Sermorelin

Sermorelin is dosed at 0.2-0.3 mg (200-300 mcg) subcutaneous daily at bedtime in adults with low IGF-1. Pediatric dosing under the former FDA-approved labeling was 30 mcg/kg/day. The adult dose is empirically derived from the pediatric program and from the GHRH physiologic replacement logic; no adult FDA NDA exists. IGF-1 should be rechecked at 6-8 weeks to confirm a response and guide dose titration.

Tesamorelin

The approved dose is 2 mg subcutaneous once daily. The phase 3 trials showing 15.2% trunk fat reduction used exactly this dose for 26 weeks [1]. There is no approved dose escalation pathway; doses above 2 mg are outside labeling and would not be covered by any payer.

Monitoring Protocol and Lab Billing

Monitoring labs generate legitimate CPT-billable encounters that keep the patient in-network even when the drug itself is out-of-pocket.

Baseline labs before initiating any GHS should include: IGF-1 (CPT 84305), fasting glucose (CPT 82947), HbA1c (CPT 83036), lipid panel (CPT 80061), and a pituitary MRI if E23.0 is the primary diagnosis code. The Endocrine Society's 2011 clinical practice guideline on adult GH deficiency states: "We recommend measuring serum IGF-1 as the primary biochemical marker of GH action and for monitoring GH therapy" [7]. This direct guideline quotation is the sentence to include verbatim in your letter of medical necessity.

Follow-up labs at 6-8 weeks: IGF-1 to confirm response. Target IGF-1 is the mid-to-upper age- and sex-adjusted reference range, not supraphysiologic. If IGF-1 exceeds the upper limit of normal, reduce dose by 25-50% and recheck in 4 weeks. Annual follow-up should include fasting glucose and HbA1c because both GH and MK-677 produce transient insulin resistance; the 2-year MK-677 data in elderly patients showed a modest but statistically significant increase in fasting glucose of 0.3 mmol/L versus placebo [4].

The American Association of Clinical Endocrinology (AACE) position on GH use in adults recommends against prescribing GH or GH-stimulating agents to patients with active malignancy, intracranial hypertension, proliferative diabetic retinopathy, or preexisting carpal tunnel syndrome without neurosurgical clearance [9].

Telehealth-Specific Billing Considerations

GHS prescribing is heavily concentrated in telehealth platforms, which creates specific CPT and place-of-service coding requirements.

Synchronous audio-video visits for GHS initiation should be billed under CPT 99205 (new patient, high complexity) or 99215 (established patient, high complexity) with place of service code 02 (telehealth provided other than in patient's home) or 10 (telehealth in patient's home), per CMS guidance updated for 2024 [10]. The medical decision-making (MDM) documentation must reflect "undiagnosed new problem with uncertain prognosis" or "prescription drug management" at high complexity to justify the level-5 code.

Add-on code 99417 (prolonged office visit, each additional 15 minutes) may apply when the initial GHS consultation exceeds 60 minutes, which is common when reviewing pituitary workup and explaining the compounding supply chain to the patient. Document the total time in the note.

Modifier 95 (synchronous telemedicine service via real-time interactive audio and video) must be appended to all E/M codes for telehealth visits with commercial payers that have not adopted place-of-service coding as the primary telehealth identifier. Check individual payer policies: United Healthcare, Cigna, and Aetna each have distinct telehealth billing manuals that differ from CMS guidance.

Safety Signals Prescribers Must Document

Documentation of safety counseling is both a clinical and a billing necessity: it supports high-complexity MDM scoring and protects against liability.

GHS agents raise IGF-1, and sustained supraphysiologic IGF-1 is associated with increased colorectal and breast cancer risk in observational epidemiology [11]. The absolute risk for any individual patient on a therapeutic GHS dose for 6-12 months is unknown, but patients must be informed and the conversation documented. The 2007 NEJM tesamorelin trial (Falutz et al., N=412) reported no malignancy signal over 26 weeks, though the authors noted the follow-up was too short to rule out long-term oncologic effects [1].

Fluid retention and carpal tunnel syndrome occur in 3-5% of patients on rhGH and have been reported anecdotally with GHS, though no large randomized trial has quantified incidence specifically for compounded ipamorelin or sermorelin. Glucose intolerance requires baseline and periodic HbA1c monitoring, as noted above. Injection site reactions are the most common adverse event in tesamorelin trials, occurring in approximately 10% of patients versus 4% placebo [5].

Prescribers should avoid GHS in patients with a history of pituitary adenoma or pituitary surgery until post-operative imaging confirms no residual tumor, because GH stimulation could theoretically promote adenoma growth. The Endocrine Society guideline [7] specifies: "Active malignancy is an absolute contraindication to GH replacement."